Vol 6, Supp. A (2010)
suplement
Published online: 2010-11-22

open access

Page views 835
Article views/downloads 5413
Get Citation

Connect on Social Media

Connect on Social Media

Do we know everything about anthracyclines in the adjuvant treatment of breast cancer?

Renata Sienkiewicz-Kozłowska, Iwona Głogowska, Dominika Jaxa-Larecka, Tadeusz Pieńkowski

Abstract

Systemic adjuvant treatment has established role in the treatment of breast cancer and anthracyclinecontaining regimens has been commonly used for over 20 years. The efficacy of these regimens has been proved in many clinical trials and meta-analyses, regardless of risk factors, age and hormonal status of patients. In search of more effective methods of treatment combination of anthracyclines and taxanes was tested and recently in the group of patients with HER2 overexpression trastuzumab was introduced to treatment. The main problem related to adjuvant treatment with anthracyclines is cardiotoxicity and that is the basis of searching new regimens and methods of treatment which would allow to eliminate or limit the use of anthracyclines in the adjuvant treatment of breast cancer
Onkol. Prak. Klin. 2010; supl. A: A1–A7

Article available in PDF format

View PDF (Polish) Download PDF file